摘要
目的评价帕利哌酮缓释片治疗精神分裂症的疗效及安全性。方法将60例符合CCMD-3诊断标准的精神分裂症患者随机分为两组,分别给予帕利哌酮缓释片和奥氮平片治疗8周。采用阳性与阴性症状量表(PANSS)、临床疗效总评量表(CGI)及治疗中出现的症状量表(TESS)评定疗效及不良反应。结果治疗结束时,两组总分及各因子分均较治疗前有显著减低(P<0.01);帕利哌酮缓释片组临床总有效率为90.0%,奥氮平组为93.3%;两组间比较差异无显著性;帕利哌酮缓释片组不良反应发生率33.3%,奥氮平组的不良反应发生率49.5%。两组间比较差异无显著性。结论帕利哌酮缓释片治疗精神分裂症的疗效与奥氮平相似,不良反应少而轻。
Objective To explore the efficacy and safety of paliperidone ER on the treatment of schizophrenia.Methods A total of 60 patients meeting the criteria of CCMD-3 for schizophrenia were randomly assigned to paliperidone ER group（n=30） or olanzapine group（n=30）for 6 weeks of treatment.The efficacy and side effects were assessed with PANSS,CGI and TESS.Results At the end of treatment,two sets of PANSS total score and factors scores were significantly lower than those before the treatment（P0.01）;The response rate were 90.0%in paliperidone ER group and 93.3% in olanzapine group,with no significant difference between two groups.The adverse reactions were 33.3% in paliperidone ER group and 49.5% in olanzapine group,and there was no significant difference between two groups.Conclusion Paliperidone ER is safe and effective with slight side effects for treating schizophrenia.
出处
《中国健康心理学杂志》
2013年第8期1133-1134,共2页
China Journal of Health Psychology
